Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by SHARKFACEon Mar 08, 2010 12:22pm

447 Views

Post# 16855987

QUOTE

Symbol

T

Bid

Ask

Last

Change

Volume

FSI

RVX CA T

+

7.11

7.14

7.14

1.12 (18.60%)

1,032,925

Bid Size	5	Ask Size	3	Earn. Per Share	-0.60
Day High	7.35	Day Low	6.51	Price/Earnings	0
Open	6.76	Yield	0.00	Dividend	0.00
52 Week High	7.37	52 Week Low	2.10	Ex-Dividend